LSD: The Neuroscience

In 1943, a Swiss chemist accidentally absorbed a trace of a compound he had shelved five years earlier, and bicycled home through a world that had come undone. The molecule was lysergic acid diethylamide — LSD — and what made Albert Hofmann’s discovery so startling was not just the intensity of the experience but the dose: he had been working with quantities so small they should have done nothing at all. Eight decades later, that same impossibility defines the science. LSD is active at a few millionths of a gram, lasts the better part of a day, and clings to its target receptor with a grip that took a crystal structure to explain. This is the neuroscience of LSD: why it is the most potent classical psychedelic ever found, what it does to the brain’s wiring, the single receptor that controls all of it, and how a molecule exiled from medicine for fifty years is being brought back through the front door.

The Molecule: A Microgram Is Enough

LSD is a semi-synthetic compound, built from lysergic acid — a substance produced by ergot, the fungus that grows on rye. Structurally it is a tryptamine fused into a rigid four-ring scaffold, and that rigidity matters: it locks the molecule into a shape that fits the serotonin receptor with extraordinary precision. The practical consequence is potency without parallel. Where an active dose of psilocybin is measured in milligrams and mescaline in hundreds of milligrams, a full dose of LSD is on the order of one hundred micrograms — a quantity so small it is invisible, delivered on a fleck of paper. Taken by mouth, effects begin within thirty to sixty minutes, build to a plateau over two to three hours, and resolve over a total of eight to twelve hours. Its blood half-life is only a few hours, which raises an obvious question the chemistry alone cannot answer: if the drug clears the bloodstream quickly, why does the experience last so long?

The Receptor: A Lock That Won’t Let Go

The answer is the receptor. Like psilocybin, mescaline, and DMT, LSD produces its effects as an agonist at the serotonin 2A (5-HT2A) receptor, densely expressed on the pyramidal neurons of the cortex. But LSD does something the others do not: it stays. In 2017, Daniel Wacker, Bryan Roth and colleagues published the first crystal structure of LSD bound to a human serotonin receptor in Cell, and it solved the puzzle of the long trip. As LSD settles into the binding pocket, a portion of the receptor — a flap of the second extracellular loop — folds down over it like a lid, trapping the molecule inside. LSD dissociates exceptionally slowly as a result; molecular-dynamics simulations confirmed the lid is the cause, and a mutation that loosens it dramatically speeds LSD’s exit and changes its signalling. The drug clears the blood in hours, but the molecules already seated on cortical receptors are held there, hour after hour. The twelve-hour experience is not a pharmacokinetic accident — it is a structural feature of the lock.

The Brain on LSD: Connection Without Borders

What does that receptor activation do to the working brain? In 2016, Robin Carhart-Harris and colleagues at Imperial College London published the first modern multimodal neuroimaging of the LSD state in PNAS — combining fMRI and MEG to watch the brain under 75µg of LSD. Two findings dominated. First, the visual cortex became massively hyper-connected to the rest of the brain; regions that normally only process incoming sight began talking to the whole cortex, and the degree of this expansion tracked the intensity of participants’ visual imagery — the neural basis of seeing with the eyes closed. Second, and inversely, the brain’s most organised system came apart: the default mode network — the midline hubs that sustain the sense of a stable, narrative self — lost its internal integrity. Connectivity between the parahippocampus and the retrosplenial cortex fell, and the size of that drop predicted the intensity of ego dissolution. The unifying picture was of a brain whose normal modular boundaries had dissolved into a single, hyper-connected whole — the “entropic brain” that has become the central metaphor of modern psychedelic neuroscience.

5-HT2A Is the Switch

How can we be sure the receptor is the cause rather than a bystander? Because blocking it makes LSD disappear. In controlled studies, giving healthy volunteers ketanserin — a selective 5-HT2A antagonist — before LSD abolishes nearly the entire experience. In a striking demonstration from Matthias Liechti’s group in Basel, administering ketanserin partway through an LSD session cut the remaining subjective effects short, shrinking the duration from roughly 8.5 hours to 3.5, and reversed the visual changes and ego dissolution as it took hold. Earlier work by Preller and colleagues had shown the same dependency: pre-treatment with ketanserin blocks LSD’s alteration of meaning and selfhood. The conclusion is as clean as pharmacology gets — the 5-HT2A receptor is not merely involved in the LSD state; it is the on-switch, and closing it turns the experience off.

The Clinic: From Gasser to MM120

LSD was an active research drug in psychiatry through the 1950s and 60s — hundreds of studies — before prohibition shut the field down for a generation. Its modern return began quietly in 2014, when Peter Gasser published the first controlled LSD trial in over forty years: a small randomized study of LSD-assisted psychotherapy for anxiety in people facing life-threatening illness. Participants who received full-dose LSD showed meaningful reductions in anxiety that were sustained at twelve-month follow-up, with no serious adverse events — a proof of principle that reopened the door. A decade later, the door is wide. MM120 — pharmaceutical-grade lysergide tartrate, developed by MindMed — ran a Phase 2b trial in nearly 200 patients with generalized anxiety disorder. A single dose produced statistically significant, dose-dependent improvement; at the optimal 100µg dose, the trial reported a 65% clinical response and 48% remission rate that held through twelve weeks from one administration. The FDA granted MM120 Breakthrough Therapy designation in 2024, the results were published in JAMA, and Phase 3 trials are now enrolling — the first serious attempt to make LSD a prescribable medicine since the 1960s.

Microdosing: The Placebo Question

No discussion of LSD today is complete without the microdose — sub-perceptual doses (typically 10–20µg) taken for claimed boosts to mood, focus, and creativity. Here the science demands honesty. The most rigorous study to date, Balázs Szigeti’s 2021 self-blinding citizen-science trial in eLife, found that microdosers did improve on measures of wellbeing and cognition — but so did the placebo group, and once expectancy was properly modelled, the difference between real and placebo microdoses vanished. Controlled laboratory studies by Bershad and colleagues found only minimal acute effects of single microdoses. There are countervailing signals — some home-administered randomized trials report genuine, if modest, acute mood elevation — but the weight of the best-controlled evidence suggests that much of microdosing’s reputation rests on expectation. That does not make the benefits people feel unreal; it makes them, at least in part, a powerful demonstration of how much the mind’s expectations shape its experience.

Set, Setting, and the Long Comedown

Because 5-HT2A receptors sit at the crossroads of perception, emotion, and meaning, the content of an LSD experience is unusually sensitive to set and setting — the mindset and environment in which it unfolds. The same dose can open onto awe or onto fear depending on context, which is why clinical protocols invest so heavily in preparation, a supportive setting, and integration. The risks are real and worth stating plainly. LSD sharply raises the salience of everything, and a difficult passage — the “bad trip” — can be acutely distressing; the twelve-hour duration means there is no quick exit. It is contraindicated for those with personal or family histories of psychosis or bipolar I, and it modestly raises heart rate and blood pressure. A minority of people experience lingering perceptual after-effects (HPPD). And because the experience is so long and so suggestible, it should never be undertaken casually, alone, or without attention to dose, source, and safety. This article is education, not medical advice.

The Synthesis

LSD is a study in disproportion. A speck too small to see opens a door that stays open for half a day, because the molecule physically locks itself into a receptor and a flap folds down to keep it there. Through that single receptor, the brain’s carefully partitioned systems dissolve into one hyper-connected whole — the visual cortex floods with meaning, the self-network comes apart, and the boundary between inner and outer thins. For decades that was a cultural story. Now it is a clinical one: blockade studies that prove the mechanism, imaging that maps the state, and trials that are, at last, testing whether the most potent psychedelic ever discovered can be turned into a medicine. The molecule Hofmann stumbled into is finally being understood on its own terms — not as a relic of the 1960s, but as one of the most revealing tools neuroscience has for asking how a brain builds a self, and what happens when it briefly stops.